We evaluated the 100-day mortality rates associated with busulfan-based myeloablative conditioning regimens based on data from 1812 chronic myelogenous leukemia patients who underwent allogeneic blood or marrow transplantation (allotx). In all, 47 patients received intravenous (i.v.) busulfan and cyclophosphamide (i.v.BuCy2) with allotx at MD Anderson Cancer Center (MDACC) during 1995-1999. The remaining 1765 patients, whose data were supplied by the International Bone Marrow Transplant Registry (IBMTR), received alternative preparative regimens, primarily Cy-total body irradiation (B45%) or oral BuCy (B35%) during 1997-1998. As patients were not randomized between conditioning regimens, the i.v.BuCy2-versus-alternative treatment effect is confounded with a possible center effect due to nontreatment differences associated with factors differing between MDACC and the IBMTR centers. Additional complications are that the i.v.BuCy2-MDACC patients all survived 100 days, and three prognostic subgroups were included. Bayesian sensitivity analyses were performed to assess treatment effect on the probability of 100-day mortality, over a range of possible MDACC-versus-IBMTR center effects. For these patients, the posterior probability that i.v.BuCy2 was superior to alternative conditioning regimens ranges from 0.54 to 0.99, depending on prognosis and the magnitude of the assumed center effect.
Summary:
We evaluated the 100-day mortality rates associated with busulfan-based myeloablative conditioning regimens based on data from 1812 chronic myelogenous leukemia patients who underwent allogeneic blood or marrow transplantation (allotx). In all, 47 patients received intravenous (i.v.) busulfan and cyclophosphamide (i.v.BuCy2) with allotx at MD Anderson Cancer Center (MDACC) during 1995-1999. The remaining 1765 patients, whose data were supplied by the International Bone Marrow Transplant Registry (IBMTR), received alternative preparative regimens, primarily Cy-total body irradiation (B45%) or oral BuCy (B35%) during 1997-1998. As patients were not randomized between conditioning regimens, the i.v.BuCy2-versus-alternative treatment effect is confounded with a possible center effect due to nontreatment differences associated with factors differing between MDACC and the IBMTR centers. Additional complications are that the i.v.BuCy2-MDACC patients all survived 100 days, and three prognostic subgroups were included. Bayesian sensitivity analyses were performed to assess treatment effect on the probability of 100-day mortality, over a range of possible MDACC-versus-IBMTR center effects. For these patients, the posterior probability that i.v.BuCy2 was superior to alternative conditioning regimens ranges from 0.54 to 0.99, depending on prognosis and the magnitude of the assumed center effect. Allogeneic hematopoietic stem cell transplantation (allotx) is a well-established curative therapy for chronic myelogenous leukemia (CML) patients. 1 The most commonly used pretransplant conditioning treatment is total body irradiation (TBI) combined with intravenous (i.v.) cyclophosphamide (Cy). 2 The delivery of TBI is very precise, but its use is burdened with a variety of complications, for example, cataracts, secondary tumors, and degraded intellectual function. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] As an alternative, high-dose oral busulfan (Bu) in combination with Cy was introduced, 13, 14 and with a subsequently modified Cy dose given over 2 days ('BuCy2'), 15 the regimen has become widely accepted; it is now the most commonly used non-TBI-based pretransplant treatment. 2 A recent randomized study suggested that longterm outcome after allotx for CML was improved when BuCy2 rather than Cy-TBI was used as the conditioning regimen. 16, 17 This is contrary to available data in the International Bone Marrow Transplant Registry 2 (IBMTR), however, where differences in outcome cannot be attributed to conditioning regimen, but only to the clinical stage of CML and whether matched related rather than matched unrelated donors have been used. The oral BuCy2 regimen is generally well tolerated, but several investigators have associated systemic Bu exposure with serious hepatic and neurologic toxicity. [18] [19] [20] [21] [22] [23] [24] In addition, the hepatic first-pass Bu exposure after oral drug administration has been suggested to contribute to veno-occlusive disease. 25 Another problem with oral BuCy2 is that the typically unpredictable and erratic intestinal absorption of Bu contributes to wide interpatient variation in bioavailability, as quantified by the area under plasma concentration vs time curve (AUC). Variability in AUC as high as 10-fold or more has been observed between patients given the same oral Bu dose. 26, 27 In addition, within-patient variability in systemic exposure, as measured repeatedly after a fixed dose given every 6 h, is also substantial, and may be as high as two-to threefold. This variability greatly contributes to uncertainty with regard to actual delivered dose. 28 Contrary to this, the various factors that influence intestinal drug absorption are completely circumvented by i.v. drug administration, and (i.v. delivery therefore yields a) 'desired concentration of a drug in bloodywith an accuracy and immediacy not possible with any other procedure', as was eloquently pointed out by Benet and Sheiner, 29 with regard to i.v. drug formulations. As precise, predictable dose exposure is very important in pretransplant conditioning therapy, we developed a pharmaceutically acceptable i.v.Bu formation. 27, 30, 31 We have demonstrated that this novel formulation yields highly reproducible pharmacokinetics (PK) with minimal within-patient variability in PK parameters and a patient-topatient variability in AUC that was reduced to two-fold, approximately. 31 Scientifically, the ideal approach to comparing the efficacy of these preparative regimens would be to embark on a confirmatory phase III study, with patients randomized between i.v.BuCy2 and a chosen 'standard' regimen, stratifying patients for clinical stage and other prognostic factors. However, at present there are some severe drawbacks with this approach. Such a randomized study would require the participation of several hundred patients and would take a long time to complete. A major problem with initiating such a study now arises from the fact that the current method for choosing an i.v.BuCy2 dose is to optimize it for individual patients using preliminary patientspecific PK information. 32 This study strongly indicated that individualized i.v.Bu dosing based on PK parameters is superior to a fixed-dose Bu-based regimen. As this withinpatient dose optimization method is still being refined, 32 it seems inappropriate to begin a long-term study of i.v.BuCy2 now. This is because it would be necessary to either continue to refine the method throughout the phase III trial or, alternatively, fix the dose optimization procedure to be a particular method that might well prove to be suboptimal midway through the trial. The former approach would introduce heterogeneity in the 'i.v.BuCy2' regimen and possibly create a drift over time in the treatment effect. The latter approach would produce results that likely would be outdated before completion of the study. Furthermore, continuing to randomize patients to such a study after a substantive improvement in the within-patient dose optimization method for i.v.BuCy2 would be undesirable for many physicians.
After treating and evaluating a series of 47 patients with i.v.BuCy2, we observed the striking result that none of these patients died within the first 100 days post transplant. This was very different from the concomitant experience with alternative (Alt) preparative regimens, as documented by the IBMTR. Consequently, we undertook a comparison of 100-day mortality between these 47 MDACC patients and 1765 IBMTR CML allogeneic transplant patients treated during a comparable time period, 1997-1998. All of the IBMTR patients received Alt preparative regimens, primarily Cy-TBI (B45%) or oral BuCy (B35%). Unfortunately, this comparison was complicated by several scientific issues. First, patients were not randomized between preparative regimens. Second, all patients who received i.v.BuCy2 were treated at MDACC while all patients receiving Alt regimens were treated at other participating IBMTR centers. Consequently, the i.v.BuCy2-versus-Alt treatment effect is confounded by other effects due to differences between the MDACC patients and the IBMTR patients not pertaining to their preparative regimens. Such differences may have arisen from variability in patient characteristics, supportive care, physicians' experience and skills, time periods of treatment, or other variables. While the effects of individual patient prognostic covariates could be accounted for by a statistical regression analysis, such data were not available for the 1765 IBMTR patients. We will refer to the composite MDACC-versus-IBMTR difference, arising from effects other than pretransplantation conditioning treatment, as the 'center effect'. In sharp contrast with the fact that none of the 47 i.v.BuCy2-MDACC patients died before day 100, the 100-day death rates of the 1765 Alt-IBMTR patients varied from 18 to 30%, depending on disease stage. Consequently, the statistical problem is to compare treatment effects between two sets of binomial samples while accounting for treatment-center confounding, prognostic subgroup, and the fact that all of the samples in one set have 0 events.
Despite the presence of treatment-center confounding, the currently available data may provide useful insights into what the actual comparative effects of the i.v.BuCy2 and Alt preparative regimens may be. We addressed the problem of comparing treatments in the presence of treatment-center confounding here by first assuming that, within each prognostic subgroup, the observed difference was the sum of a hypothetical treatment effect and a center effect. A Bayesian model, 33, 34 under which each of the effects of interest is considered to be a random quantity, was assumed. We performed a sensitivity analysis under which the putative center effect was varied over a range of values, accounting for anywhere from none to all of the observed difference, and the resulting treatment effect was computed. This is similar to the method used by Estey et al, 35 to evaluate possible treatment effects in the presence of treatment-trial confounding. While our Bayesian sensitivity analysis is not a substitute for a randomized trial, it can be used as a means to assess what the unknown treatment effects are likely to be. This may be used, in turn, as a basis for deciding whether to proceed with a prospective randomized trial, as well as making therapeutic decisions in the clinic during the time that the delivery of i.v.Bu is optimized, and also subsequently while future long-term randomized studies of i.v.Bu-based conditioning therapy vs Alt regimen(s) are ongoing.
Patients and treatments
We treated 47 consecutive CML patients undergoing allotx for various stages of their disease at MDACC from July 1996 to October 1999. Of these patients, 17 were in chronic phase (CP), 25 were in accelerated phase (AP), and 5 were in blast crisis (BC) at the time of allotx. In all, 29 (62%) were male and 18 (38%) were female, with median age 40 years (range, 19-64 years). The median time from diagnosis to transplant, in months, was 17 for CP (range, 2-244 months), nine for AP (range, 2-77 months), and 18 for BC (range, 4-111 months). The pretransplant conditioning regimen consisted of i.v.Bu at 0.8 mg/kg body weight over 2 h every 6 h for 16 doses, followed by two daily doses of Cy at 60 mg/kg ('i.v.BuCy2'). 31 The drugs were used as a fixeddose i.v.BuCy2 regimen without PK-guided individualized dose adjustment. In total, 30 patients received bone marrow and 17 received peripheral blood progenitor cells from HLA-matched related donors. The graft-versus-host disease prophylaxis was tacrolimus and minidose methotrexate.
The comparison group consisted of 1765 IBMTR CML transplant patients who received Alt preparative regimens. Of these patients, 1344 (76%) were in CP, 335 (19%) were in AP, and 86 (5%) were in BC. The IBMTR patients received Alt preparative regimens, most commonly Cy-TBI or oral BuCy2. 2 
Statistical methods

Conventional comparisons
The 100-day mortality data of the i.v.BuCy2-MDACC patients and Alt-IBMTR patients, within each CML prognostic subgroup and also overall for the combined prognostic groups, were compared using Fisher's exact test.
Bayesian model
The basic principles of the Bayesian paradigm and properties of the binomial and beta probability models used here are described in the appendix. To establish the Bayesian probability model, for simplicity, we temporarily limit attention to patients in a single prognosis and treatmentcenter combination, denoted by p, the probability of a given patient in the subgroup dying within 100 days. Here, we assume that, a priori, before any data are observed, pBbeta[ 
Bayesian comparisons
Temporarily focus attention on one prognostic subgroup, and denote the 100-day mortality probabilities by p 1 for the i.v.BuCy2-MDACC patients and p 2 for the Alt-IBMTR patients. We will compare the Alt-IBMTR and i.v.BuCy2-MDACC groups in terms of the posterior distributions of their 100-day mortality probabilities, p 2 and p 1 . A useful method is to graph the posteriors of p 1 and p 2 and compare them visually. A single statistic that summarizes the difference between p 1 and p 2 is Pr(p 2 4p 1 |Data), the posterior probability that the Alt-IBMTR patients had a higher 100-day mortality rate than the i.v.BuCy2-MDACC patients, given the observed data in the two subgroups. If the posteriors of p 1 and p 2 were identical, then this probability would be 1 2 . Values greater (less) than 1 2 correspond to a lower (higher) 100-day death rate in the i.v.BuCy2-MDACC patients. To obtain an overall comparison based on the combined prognostic subgroups, we computed a weighted average of the three posterior probabilities from the CP, AP, and BC subgroups, with the weights proportional to the three sample sizes. From Table 1 
Bayesian sensitivity analyses
Again, for simplicity, temporarily consider a single prognostic subgroup. All of the distributions discussed here are posteriors, that is, conditional on the observed data. Since Pr(p 2 4p 1 |Data) ¼ Pr(p 2 Àp 1 40|Data), we will focus on the difference of the two 100-day mortality probabilities, p 2 Àp 1 , which is the comparative effect due to Alt-IBMTR vs i.v.BuCy2-MDACC. The main difficulty is that p 2 Àp 1 is not the effect of interest, namely the treatment effect, Alt-vs Table 1 Survival (100 days) by preparative regimen, center, and CML prognostic subgroup # Deaths within 100 days/# patients (%) Fisher's exact test P-value Probability i.v.BuCy2-MDACC has lower 100-day mortality than Alt-IBMTR (Table 1) . Thus, if there is a center effect, it almost certainly constitutes an advantage due to being treated at MDACC compared to the centers contributing to the IBMTR data.
Fix a value of p between 0 and 1. We will assume that the proportion p of p 2 Àp 1 is due to center and the remaining 1Àp is due to treatment. Denote by p 1 (p) the corresponding hypothetical 100-day mortality probability of an i. . That is, we assume that, given the data, the hypothetical 100-day mortality probability of an i.v.BuCy2 patient, with center effects removed, follows a beta distribution with mean m 1 (p) ¼ (1Àp)m 1 þ pm 2 and effective sample size N 1 , the same as that of p 1 . These assumptions ensure that, while the mean of the hypothetical probability p 1 (p) equals an average of the means of p 1 and p 2 , the amount of information in the posterior of p 1 (p) is the same as the amount of information in the posterior of (1) has the same mean as p 2 (but a smaller variance), all of the observed effect is due to center, there is no treatment effect, and Pr(p 2 4p 1 (p)|Data) is approximately 1 2 . This probability is not exactly 1 2 due to the difference in variances. Given this structure, the sensitivity analysis consists of evaluating Pr(p 2 4p 1 (p)|Data) as p is varied between 0 and 1. We did this for each prognostic subgroup, and also for the weighted average of the three subgroups. Table 1 summarizes the raw data, P-values of the Fisher's exact tests comparing the observed mortality rates in each prognostic group and overall, and the corresponding Bayesian posterior probabilities that one rate is lower than the other. Within each row of Table 1 , both the Fisher's exact test P-value and the Bayesian comparison reflect the difference between the confounded treatment-center effects, namely i.v.BuCy2-MDACC-versus-Alt-IBMTR, rather than the i.v.BuCy2-versus-Alt treatment effect. Thus, these comparisons are potentially misleading in that they ignore treatment-center confounding and compare the combined effect of receiving i.v.BuCy2 at MDACC to the combined effect of receiving an Alt preparative regimen at an IBMTR center. The Fisher's exact tests show that, using the conventional cutoffs 0.10, 0.05 and 0.01 for the test P-values to quantify 'marginal significance', 'significance' and 'high significance', respectively, the difference is marginally significant in CP patients, highly significant in AP patients, and not significant in BC patients. If one ignores CML stage, then an overall test has P-value o0.001, which is highly significant.
Results
From a Bayesian perspective, among the i.v.BuCy2-MDACC patients in CP, observing that 0/17 died within 100 days (Table 1) gives a beta( Figure 1d for the combined subgroups is obtained as a weighted average of three individual subgroup posteriors. The numerical values on the vertical axes in Figure 1 reflect the fact that the total area under each curve must equal 1, since it is a probability distribution.
The comparisons provided by Figure 1 clearly indicate that, within each prognostic subgroup and overall, the i.v.BuCy2-MDACC patients had a much smaller probability of 100-day mortality than the Alt-IBMTR patients. The last column of Table 1 gives the posterior probability Pr(p 2 4p 1 |Data) corresponding to each of these visual comparisons.
i.v. BuCy2 vs other pretransplant therapy in CML PF Thall et al Table 2 summarizes the results of four similar Bayesian sensitivity analyses, one within each prognostic subgroup and one for the combined subgroups. In each analysis, we assume that a varying proportion of the observed effect is due to an MDACC-versus-IBMTR center effect. As a basis for comparison, the first column of the table, labeled '0%', gives the probability Pr(p 2 4p 1 |Data), within i.v. each subgroup and overall, that 100-day mortality was lower in the i.v.BuCy2-MDACC patients compared to the Alt-IBMTR patients, thus comparing the two confounded treatment-center effects. The last four columns give the probability Pr(p 2 4p 1 (p)|Data) for p ¼ 0.25, 0.50, 0.75, and 1.00, respectively, quantifying the hypothetical treatment effects that result from assuming that 25, 50, 75, or 100% of the confounded treatment-center effect is due to center. In all three CML prognostic subgroups, even if half (50%) of the observed advantage is due to an intrinsic superiority of MDACC over the IBMTR centers, then the probability that i.v.BuCy2 has lower 100-day mortality compared to Alt preparative regimens still varies from 0.78 to 0.94, depending on prognostic subgroup. Only under the extreme assumption that 100% of the observed difference is due to MDACC center superiority over the IBMTR do the probabilities of i.v.BUCy2 treatment superiority drop to values near 0.50.
The sensitivity analyses are illustrated graphically in Figure 2 . Each plot varies the assumed percentage of the confounded treatment-center effect that is due to center continuously from 0 to 100. For each CML subtype, the lowest mean center effect value of 0% corresponds to the assumption that there is no MDACC-versus-IBMTR center effect. The highest value of 100% corresponds to the assumption that, on average, all of the observed difference is due to an MDACC-versus-IBMTR advantage.
Rather than first fixing the value of p, the proportion of the confounded effect that is due to superiority of MDACC, and then computing Pr(p 2 4p 1 (p)|Data), one may perform the computation in reverse. That is, one may first fix the posterior probability Pr(p 2 4p 1 (p)|Data) at a given critical threshold and then solve for p. Table 3 provides values of p, expressed as the percentage 100p, for the critical thresholds Pr(p 2 4p 1 (p)|Data) ¼ 0.80, 0.85, 0.90, and 0.95.
More generally, one may assume a probability distribution f(p) on p, the proportion of the posterior mean of p 1 (p) that may be attributed to center effect, and compute the average of Pr(p 2 4p 1 (p)|Data) over f(p). This formalizes Table 2 may be regarded as a special case of the above in which f(p) places probability 1 on a single value of p. This computation could be done for one or more hypothetical distributions on p, each reflecting a different opinion with regard to center effects. In general, the computation would require numerical integration of Pr(p 2 4p 1 (p)|Data)f(p) for p ranging from 0 to 1. However, one may easily do the computation in an approximate way by placing all of the probability mass of f(p) on the five values of p given in Table 2 and using the values of Pr(p 2 4p 1 (p)|Data) given there. For example, if one feels it is most likely that about p ¼ 0.50 of the observed effect is due to MDACC superiority, but allows with some small probabilities both of the possibilities that all or none of the observed effect is due to center, then the distribution Figure 2 Bayesian sensitivity analyses. Each plot gives the posterior probability that 100-day mortality is lower with i.v.BuCy2 compared to Alt preparative regimens, as the assumed percentage of the confounded treatment-center effect that is due to center is varied between 0 and 100. suffer from the possibility that apparent treatment effects may, in fact, be due to differences in patient prognostic covariates. Even when such covariate data are available, there is still the concern that apparent treatment effects may be due in part to differences in clinical supportive care routines, as well as differences in training and experience of the medical and nursing staffs at the various medical centers.
The most striking feature of the early post transplant course of the 47 MDACC patients was that none died during the first 100 days post transplantation, the time period commonly considered most critical for immune recovery, and also the period during which the acute toxicity/safety of the conditioning regimen is usually assessed. In contrast, the IBMTR patients had 100-day mortality rates of 18% for those transplanted in CP, 25% in AP, and 30% in BC. Based on these data, it might appear that one may infer through standard statistical methods that i.v.BuCy2 is superior to Alt regimens with regard to 100-day mortality of CML patients receiving allotx. As explained above, however, the presence of treatment-center confounding in these data severely limits the reliability of standard statistical analyses. These problems, the absence of individual prognostic covariates for the IBMTR patients, and the possibility of supportive care effects, together motivated us to perform the Bayesian sensitivity analyses described here. We have argued that a Bayesian sensitivity analysis can provide a basis for evaluating treatment effects even in the presence of possible confounding effects.
Our Bayesian sensitivity analyses lead to the general conclusion that, if the observed differences in 100-day mortality rates are attributable to the sum of a center effect and a treatment effect, then one must conclude that i.v.BuCy2 is superior to Alt preparative regimens, that MDACC is superior to IBMTR centers, or that some combination of these two effects is the case. Since the outcome of the patients treated with i.v.BuCy2 is significantly better than what would be expected from the results available from a large number of centers participating in the IBMTR, one may be tempted to conclude that the i.v.Bu as used in the i.v.BuCy2 regimen represents a significant improvement for patient survival, at least in the first 100 days after allotx. Alternatively, if the observed difference is due to a center effect, as defined above, then one must conclude that the MD Anderson Cancer Center allotx program is superior to most other transplant programs. We are less inclined to favor the latter explanation as the most significant contributor to the observed difference in early post transplant outcome. First, post transplantation supportive care is very similar between different centers, with only minor alterations between programs. Second, the training and sharing of experience of the medical staff are similar in different programs and recruitment and exchange of staff between programs are also significant over time. The MDACC BMT program is no exception in this respect. Lastly, a number of clinical allotx studies using other myeloablative, or near-myeloablative, conditioning programs during the time period 1995-2001 have been published from the MDACC. In these publications, the 100-day mortality rate has varied from 25 to 37%. [36] [37] [38] [39] [40] [41] [42] [43] It thus appears that the more consistent delivery of Bu that is achieved with a parenteral formulation is likely to have a significant impact on early post transplant mortality in the studied patient population. Further support for the notion that more consistent Bu delivery may impact early treatment-related mortality in CML patients undergoing allotx was recently provided by Radich et al. 44 These investigators reported that continuous PK monitoring and repeated Bu dose adjustments resulted in a low (3%, with 95% confidence interval 1-8%) 100-day treatment-related mortality in 131 mostly early CP patients (median time from diagnosis to BMT 5 months, with 87% transplanted within 1 year from diagnosis), who were conditioned with oral Bu and i.v.Cy in a PK-dosageadjusted BuCy2 schedule during 1995-2000. While the inference that consistent and reliable Bu delivery is of major importance for controlling overall treatment-related mortality can be confirmed only by conducting a randomized phase III trial, until such data become available it seems appropriate when making therapeutic decisions in allotx to consider the currently available CML data in light of the results of the Bayesian sensitivity analyses reported here.
